Cite

HARVARD Citation

    Fisk, M. et al. (2021). Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19. Pulmonary pharmacology & therapeutics. p. . [Online]. 
  
Back to record